Chen-Yi Yuan, Yuan-Cheng Gao, Yi Lin, Lin Liu, Xiao-Gang Shen, Wen-Li Zou, Min-Min Wang, Quan-Quan Shen, Li-Na Shao, Yue-Ming Liu, Jia-Wei Zhang, Zhi-Hui Pan, Yan Zhu, Jing-Ting Yu, Xu-Guang Yu, Bin Zhu
BACKGROUND: Mineralocorticoid receptor blockade could be a potential approach for the inhibition of chronic kidney disease (CKD) progression. The benefits and harms of different mineralocorticoid receptor antagonists (MRAs) in CKD are inconsistent. OBJECTIVES: The aim of the study was to summarize the benefits and harms of MRAs for CKD patients. METHODS: We searched MEDLINE, EMBASE, and the Cochrane databases for trials assessing the effects of MRAs on non-dialysis-dependent CKD populations...
2024: American Journal of Nephrology